Reductions in Hiv-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials

摘要: Objectives: Four randomized double-blind trials have demonstrated that zidovudine/lamivudine (ZDV/3TC) reduces HIV RNA and raises CD4 counts relative to control treatments [ZDV or ZDV/zalcitabine (ddC)]. A meta-analysis of the clinical events in these was conducted determine whether treatment with ZDV/3TC also associated a benefit. Design: The four trials, versus ZDV (NUCA3001, NUCB3001, NUCB3002) ZDV/ddC (NUCA3002), were run concurrently, using same doses 3TC. Setting: Investigational sites Europe North America. Patients: recruited 972 HIV-1-positive, male female patients aged ≥18 years, 100-500 cells x 10 6 /l. Two for ZDV-naive two pre-treated patients. Main outcome measures: Progression first new Centers Disease Control Prevention (CDC) B C event compared between all arms (ZDV, ZDV/ddC) arms. Results: total 118 progressed CDC B/C during while 28 event. Meta-analysis showed 49% reduction progression (relative risk, 0.509; 9.5% confidence interval, 0.365-0.710; P < 0.0001) 66% 0.344; 95% 0.169-0.700; P= 0.003) Reductions disease seen subgroups naive patients, those high low symptomatic asymptomatic Conclusions: combination delays treatments. In view incidence events, results should be interpreted caution.